NEWS
PRESS CENTER
2019
2021-08-25
- In January, we received IND approval for Phase I/II clinical trial of LAE001 for mCRPC from NMPA in China
- In May, we received IND approval for Phase I LAE002 and LAE001 combination MRCT study in patients with mCRPC from FDA in the United States
- In November, we received IND approval for pivotal Phase II MRCT study of LAE002 plus paclitaxel versus paclitaxel in patients with PROC from FDA in the United States
Recommendation
-
2024-11-20Laekna Announces a Clinical Collaboration with Lilly to Develop LAE102, a Novel Monoclonal Antibody Targeting Activin Receptor Type 2A for The Treatment of ObesityMore -
2024-06-26Laekna Announces First Subject Dosed in Phase I Clinical Trial of LAE102 (a monoclonal antibody against ActRIIA) in China for The Treatment of ObesityMore
RSS Feeds
If you want to know more about Laekna, please fill in the form below and sign up for emails:
Follow us on Linkedin
Copyright © Laekna Therapeutics, All Rights Reserved. 沪ICP备17047795号 Privacy Policy
